RT Journal Article
SR Electronic
T1 Intrahost evolution and forward transmission of a novel SARS-CoV-2 Omicron BA.1 subvariant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.25.22275533
DO 10.1101/2022.05.25.22275533
A1 Ana S. Gonzalez-Reiche
A1 Hala Alshammary
A1 Sarah Schaefer
A1 Gopi Patel
A1 Jose Polanco
A1 Angela A. Amoako
A1 Aria Rooker
A1 Christian Cognigni
A1 Daniel Floda
A1 Adriana van de Guchte
A1 Zain Khalil
A1 Keith Farrugia
A1 Nima Assad
A1 Jian Zhang
A1 Bremy Alburquerque
A1 Levy Sominsky
A1 Komal Srivastava
A1 Robert Sebra
A1 Juan David Ramirez
A1 Radhika Banu
A1 Paras Shrestha
A1 Alberto Paniz-Mondolfi
A1 Emilia Mia Sordillo
A1 Viviana Simon
A1 Harm van Bakel
YR 2022
UL http://medrxiv.org/content/early/2022/05/27/2022.05.25.22275533.abstract
AB Persistent SARS-CoV-2 infections have been reported in immune-compromised individuals and people undergoing immune-modulatory treatments. It has been speculated that the emergence of antigenically diverse SARS-CoV-2 variants such as the Omicron variant may be the result of intra-host viral evolution driven by suboptimal immune responses, which must be followed by forward transmission. However, while intrahost evolution has been documented, to our knowledge no direct evidence of subsequent forward transmission is available to date.Here we describe the emergence of an Omicron BA.1 sub-lineage with 8 additional amino acid substitutions within the spike (E96D, L167T, R346T, L455W, K458M, A484V, H681R, A688V) in an immune-compromised host along with evidence of 5 forward transmission cases. Our findings show that the Omicron BA.1 lineage can further diverge from its exceptionally mutated genome during prolonged SARS-CoV-2 infection; highlighting an urgent need to employ therapeutic strategies to limit duration of infection and spread in vulnerable patients.Competing Interest StatementThe Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays listing Viviana Simon as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Robert Sebra is VP of Technology Development and a stockholder at Sema4, a Mount Sinai Venture. This work, however, was conducted solely at Icahn School of Medicine at Mount Sinai.Funding StatementThe work reported was in part supported by a contract from the National Institute of Allergy and Infectious Diseases (75N93021C00014, Option 12A) awarded to the Center for Research on Influenza Pathogenesis and Transmission (a Center of Excellence for Influenza Research and Response) as part of the SARS-CoV-2 Assessment of Viral Evolution (SAVE) Program, a contract from the National Institute of Allergy and Infectious Diseases (HHSN272201400008C) awarded to the Center for Research on Influenza Pathogenesis (a Center of Excellence for Influenza Research and Surveillance), philanthropic donations from the JPB Foundation, a research grant (2020-215611 [5384]) from the Open Philanthropy Project, and awards (S10OD026880 and S10OD030463) from the NIH Office of Research Infrastructure Programs.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were reviewed and approved by the Mount Sinai Hospital Institutional Review Board for the collection and viral genome sequencing of residual diagnostic specimens by the Pathogen Surveillance Program (protocol HS# 13-00981).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript or available upon reasonable request to the authors https://www.gisaid.org